Singapore-headquartered biotechnology company ASLAN Pharmaceuticals, which focuses on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has concluded an initial public offering (IPO) of common shares via public lottery.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
